WO2023162065A1 - 生体試料保存剤、生体試料保存剤の製造方法、生体試料保存方法及び生体試料保存のためのキット - Google Patents
生体試料保存剤、生体試料保存剤の製造方法、生体試料保存方法及び生体試料保存のためのキット Download PDFInfo
- Publication number
- WO2023162065A1 WO2023162065A1 PCT/JP2022/007491 JP2022007491W WO2023162065A1 WO 2023162065 A1 WO2023162065 A1 WO 2023162065A1 JP 2022007491 W JP2022007491 W JP 2022007491W WO 2023162065 A1 WO2023162065 A1 WO 2023162065A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- biological sample
- preservative
- mol
- monovalent cation
- polyatomic monovalent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/12—Chemical aspects of preservation
- A01N1/122—Preservation or perfusion media
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/04—Preserving or maintaining viable microorganisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/52—Chemical aspects of preservation of animal cells or human cells
- C12N5/522—Preservation media
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
Definitions
- the present disclosure relates to a biological sample preservative for preserving a biological sample, a method for producing a biological sample preservative, a method for preserving a biological sample, and a kit for preserving a biological sample.
- Patent Document 1 describes a cryopreservation solution characterized by containing modified polyvinyl alcohol having an ethylene oxide group. Specifically, after immersing living cells or tissues in an equilibration solution, the cells or tissues are taken out together with a small amount of the equilibration solution using a pipette or other thin tubular jig, and transferred to a cryopreservation solution. .
- the cells or tissues are immersed in the cryopreservation solution for a predetermined time, they are taken out together with a small amount of the cryopreservation solution, and the cells or tissues are dropped onto the sheet of the cryopreservation jig together with a small amount of the cryopreservation solution. . After that, the sheet on which the cells or tissues are placed is immersed in a cooling medium such as liquid nitrogen and frozen. According to the preservation technique described in Patent Document 1, cells and tissues of a living body are preserved through the steps described above.
- an object of the present disclosure is to provide a novel biological sample preservative that enables preservation of a biological sample at room temperature, a method for producing the biological sample preservative, a method for preserving a biological sample, and a kit for preserving a biological sample. do.
- the present disclosure discloses a substance having 1.0 to 10.0 mol/L of a polyatomic monovalent cation represented by the chemical formula NH4 + or composed of the polyatomic monovalent cation
- the present inventors have found a biological sample preservative that enables preservation at room temperature by containing a compound that Therefore, the first aspect of the present disclosure is (1) a substance having 1.0 to 10.0 mol/L of a polyatomic monovalent cation represented by the chemical formula NH4 + or composed of the polyatomic monovalent cation
- a biological sample preservative comprising a compound that
- the concentration of the substance having the polyatomic monovalent cation or the compound composed of the polyatomic monovalent cation is 1.7 to 5.0 mol/L.
- the substance having polyatomic monovalent cations or the compound composed of polyatomic monovalent cations includes at least one of ammonium sulfate and ammonium nitrate, and (1) ) or the biological sample preservation agent according to (2).
- a preferred embodiment of the present disclosure is (4) the biological sample preservation agent according to any one of (1) to (3) above, further comprising 0.004 to 10.000 mol/L of a chelating reagent. .
- a preferred aspect of the present disclosure is (5) the biological sample preservative according to (4) above, wherein the chelating reagent has a concentration of 0.006 to 0.500 mol/L.
- a preferred aspect of the present disclosure is (6) the biological sample preservation agent according to (4) above, wherein the chelating reagent contains at least one of sodium citrate and trisodium citrate monohydrate. .
- a preferred embodiment of the present disclosure is (7) the biological sample preservation agent according to any one of (1) to (6) above, further comprising a buffering agent of 0.004 to 10.000 mol/L.
- a preferred aspect of the present disclosure is (8) the biological sample preservative according to (7) above, wherein the buffer has a concentration of 0.010 to 5.000 mol/L.
- a preferred aspect of the present disclosure is (9) the biological sample preservation agent according to (7) or (8) above, wherein the buffer is ethylenediaminetetraacetic acid.
- a preferred embodiment of the present disclosure is (10) the biological sample preservation agent according to any one of (1) to (9) above, further comprising 0.25 to 30% by weight of an excipient.
- a preferred aspect of the present disclosure is (11) the biological sample preservation agent according to any one of (1) to (10) above, which is a freeze-dried powder.
- the present inventors have found a substance having a polyatomic monovalent cation represented by the chemical formula NH4 + at 1.0 to 10.0 mol/L or from the polyatomic monovalent cation
- a method for producing a biological sample preservative that enables storage at room temperature by containing the constituent compound. Therefore, another aspect of the present disclosure is (12) a substance having a polyatomic monovalent cation represented by the chemical formula NH4 + at 1.0 to 10.0 mol/L in a predetermined solvent, or the polyatomic monovalent cation
- a method for producing a biological sample preservative, comprising a first addition step of adding a compound composed of ions.
- a preferred embodiment of the present disclosure further comprises (13) a second addition step of further adding 0.25 to 30% by weight of an excipient to the solution obtained by the first addition step, A method for producing a biological sample preservative according to (12).
- a preferred embodiment of the present disclosure is (14) above (13), further comprising a freeze-drying step of freeze-drying the solution obtained in the second addition step at -10°C to -100°C. and a method for producing the biological sample preservative of
- a preferred embodiment of the present disclosure is (15) the dehydration step of dehydrating the solution obtained in the first addition step under heating conditions or vacuum conditions, according to (12) above.
- a method for producing a biological sample preservative is (15) the dehydration step of dehydrating the solution obtained in the first addition step under heating conditions or vacuum conditions, according to (12) above.
- a substance having a polyatomic monovalent cation represented by the chemical formula NH4 + at 1.0 to 10.0 mol/L or from the polyatomic monovalent cation A method of preserving a biological sample using a biological sample preservative solution containing a compound composed of the present invention has been found. Therefore, another aspect of the present disclosure is (16) a substance having 1.0 to 10.0 mol/L of a polyatomic monovalent cation represented by the chemical formula NH4 + or composed of said polyatomic monovalent cation including a preservation step of immersing the biological sample in a biological sample preservative solution containing the compound and preserving the biological sample at room temperature.
- kits for biological sample preservation that includes a biological sample preservation agent comprising a compound that is composed. Therefore, another aspect of the present disclosure is (17) a substance having 1.0 to 10.0 mol/L of a polyatomic monovalent cation represented by the chemical formula NH4 + or composed of said polyatomic monovalent cation
- a kit for biological sample preservation, comprising a biological sample preservation agent comprising a compound comprising a compound.
- the present disclosure can provide a novel biological sample preservative that enables preservation of a biological sample at room temperature, a method for producing a biological sample preservative, a method for preserving a biological sample, and a kit for preserving a biological sample.
- FIG. 1 shows the results of 24 hours at 37° C. of mouse liver in the stock solution, 1/2 dilution, 1/4 dilution, and phosphate-buffered saline prepared as a negative control of the biological sample preservative of Example 1.
- FIG. 11 shows an image of each microtube after storage.
- FIG. 10 is a diagram showing images of microtubes after mouse livers were preserved at 37° C. for 24 hours in the biological sample preservative solutions of Examples 1 to 9 and in phosphate-buffered saline prepared as a negative control. be.
- Embodiments for carrying out the biological sample preservative, the method for producing the biological sample preservative, and the method for preserving the biological sample of the present disclosure will be described in detail below. However, the following embodiment is an example for explaining the present disclosure, and the present disclosure is not limited only to the embodiment.
- the biological sample preservative can be produced by, for example, adding each component to a predetermined solvent, and optionally a freeze-drying step or dehydration step. .
- the manufacturing process will be specifically described below.
- a biological sample is a sample collected from or used for a living body, and includes organs, tissues, cells (including cultured cells), body fluids, nucleic acids, proteins, or combinations thereof. is. More preferably, nucleic acids, proteins, or combinations thereof are used as biological samples. In addition to samples collected from living organisms, these biological samples may include samples artificially synthesized for living organisms. Moreover, the invention according to the present disclosure is not necessarily limited to the examples exemplified here.
- the biological sample preservative to be manufactured is preferably provided in the form of a solution during preservation of living organisms, but may be in any form such as dry form, solid form, powder form, anhydrous form, and granular form. may When the biological sample preservative is in a form other than a solution, it is preferably used after being dissolved in a predetermined solvent so as to obtain a desired concentration. Moreover, the invention according to the present disclosure is not limited to these forms.
- the biological sample preservative to be manufactured may be provided as a preservative or preservative composition having the above-described form. It may be provided as a kit for biological sample storage containing.
- First addition step in the present disclosure, a required amount of a predetermined solvent is put into a container and stirred at room temperature of 5 to 50°C, more preferably 10 to 40°C. Pure water is typically used as the solvent, but treated water such as filtered water, purified water, distilled water, deionized water, or combinations thereof, which has been treated by filtration, distillation, deionization, or a combination thereof; , water containing these treated water may be used.
- treated water such as filtered water, purified water, distilled water, deionized water, or combinations thereof, which has been treated by filtration, distillation, deionization, or a combination thereof.
- a buffering agent is then added at a predetermined concentration to the stirred solvent.
- Buffers to be added include phosphate buffer, Tris-HCl buffer, ethylenediaminetetraacetic acid buffer, Tris-ethylenediaminetetraacetic acid buffer, Trisacetic acid-ethylenediaminetetraacetic acid buffer, Tris-borate-ethylenediaminetetraacetic acid buffer, Various buffers such as SSC buffers, SSPE buffers, sodium citrate buffers, carbonate-bicarbonate buffers, sodium borate buffers, 2-morpholinoethanesulfonic acid buffers and combinations thereof can be used. is. Among these, ethylenediaminetetraacetic acid buffer is more preferably used as the buffer.
- the invention according to the present disclosure is not limited to these buffer solutions.
- the buffer solution is added so as to have a concentration of 0.004 to 10.000 mol/L, more preferably 0.010 to 5.000 mol/L in the final biological sample preservative. .
- each material such as other main components and additive materials is added to the solution to which the buffer solution has been added.
- Principal components include substances having polyatomic monovalent cations represented by the chemical formula NH4 + or compounds composed of said polyatomic monovalent cations. Such substances or compounds are selected from the group consisting of ammonium sulfate, ammonium nitrate and combinations thereof.
- a substance having a polyatomic monovalent cation represented by NH4 + or a compound composed of the polyatomic monovalent cation that is, a substance or compound containing an ammonium ion
- a biological sample can be stored at room temperature. It is possible to further enhance the effect and storage stability. Note that the invention according to the present disclosure is not limited to these buffer solutions.
- a substance having a polyatomic monovalent cation represented by the chemical formula NH4 + or a compound composed of the polyatomic monovalent cation is 1.0 to 10.0 mol/ L, more preferably added to a concentration of 1.7 to 5.0 mol/L.
- chelating agents can include sodium citrate, trisodium citrate monohydrate, sodium borate, sodium fluoride, ethylenediaminetetraacetic acid, or combinations thereof. By adding these chelating reagents, it is possible to suppress the action of nucleolytic enzymes and further improve the storage stability of biological samples such as nucleic acids at room temperature. Note that the invention according to the present disclosure is not limited to these chelating reagents.
- the chelating reagent is added so that the final biological sample preservative will have a concentration of 0.004 to 10.000 mol/L, more preferably 0.006 to 0.500 mol/L.
- stabilizers include 4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride, aprotinin, E-64, leupeptin hemisulfate monohydrate, silicon carbide, 4-hydroxybenzoic acid, N,N- Dialkylpropanamide (N,N-dialkylpropanamide), 3-morpholinopropanesulfonic acid, polyethylene glycol, poly(oxyethylene) polymer, poly(oxyethylene) polymer, monoethylene glycol (1,2-ethanediol) (mono-ethylene glycol (1,2-ethanediol)), glutathione, lithium salt, chaotropic agent, guanidinium salt, guanidine hydrochloride, urea, polyamines, biuret, arginine, cosmo Various substances such as trope, polyethylene glycol, polyvinylpyrrolidone, arginine ethyl ester, glycine
- stabilizing agents biological samples such as cells, proteins, and nucleic acids can be stabilized. Furthermore, among these, 4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride, aprotinin, E-64, leupeptin hemisulfate monohydrate or a combination thereof inhibits protease activity. , in particular the stability can be increased. It should be noted that the invention according to the present disclosure is not limited to these stabilizers. The amount of these stabilizers to be added can be appropriately adjusted according to the selected stabilizer. Or if a combination thereof is selected, it can be added at a concentration of 0.001 to 1.0 wt%, more preferably 0.01 to 0.10 wt%.
- bactericidal and antimicrobial agents include amoxicillin trihydrate, cefotaxime sodium, clarithromycin, erythromycin, pyrethrins, metofruthrin, transfluthrin, sodium azide, 4-hydroxybenzoic acid, alcohols, surfactants or their Various things such as combinations can be used. It should be noted that the invention according to the present disclosure is not limited to these bactericidal/antibacterial agents. The amount of these bactericidal and antibacterial agents added can be appropriately adjusted according to the selected stabilizer, but it is added at a concentration of 0.001 to 1.0% by weight, more preferably 0.01 to 0.10% by weight. It is possible to
- additives such as surfactants, pH adjusters, and colorants may be included as appropriate in addition to the above components.
- Freeze-drying process For the biological sample preservative produced as described above, in consideration of the ease of storage and transportation of the biological sample preservative itself, it is further divided into dry form, solid form, powder form, anhydrous form, and granule form. It is also possible to process it into a given solid shape such as By subjecting the biological sample preservative (solution) produced as described above to a freeze-drying process, it is possible to obtain the biological sample preservative in these forms. Note that the freeze-drying step is not an essential step, and can be performed as desired.
- Second addition step First, in the freeze-drying step, as the second addition step, an excipient is added to the biological sample preservative (solution) produced as described above and dissolved by stirring.
- excipients include polyols, monosaccharides, disaccharides, polysaccharides, amino acids, peptides, proteins, hydrophilic polymers or combinations thereof.
- excipients preferably include lactose, glucose, sucrose, crystalline cellulose, calcium sulfate, calcium carbonate, talc, titanium oxide, erythritol, mannitol, sorbitol, trehalose, sucrose, methylcellulose, hydroxypropylcellulose, hydroxy Propylmethylcellulose, carmellose sodium, pullulan, dextrin, gum arabic, agar, gelatin, tragacanth, sodium alginate, polyvinylpyrrolidone, polyvinyl alcohol, or combinations thereof are preferred, and calcium carbonate, dextrin, or combinations thereof are particularly preferred. is possible.
- the invention according to the present disclosure is not limited to these excipients.
- the amount of these excipients to be added can be appropriately adjusted according to the selected excipient, but it is preferable to add them at a concentration of 0.25 to 30% by weight, more preferably 0.1 to 10.0% by weight. It is possible.
- the biological sample preservative produced as described above is a substance having a polyatomic monovalent cation represented by the chemical formula NH4 + or a compound composed of the polyatomic monovalent cation, typically ammonium sulfate or Contains ammonium nitrate. For this reason, if the product is dehydrated and then frozen in the freeze-drying, the freezing point is rapidly reached, and there is a risk that ammonium sulfate and the like will explode in the freeze-drying apparatus. In the present disclosure, it is possible to prevent this explosion by adding a predetermined amount of excipient in advance in the freeze-drying step as described above.
- freeze-drying process When the excipients are dissolved in the biological sample preservative, freeze-drying is performed on the solution in which the excipients are dissolved as the freeze-drying process.
- a solution in which excipients are dissolved is degassed under vacuum conditions for a predetermined time (e.g., 60 minutes), and then at a predetermined temperature (e.g., , ⁇ 75° C.) for a predetermined time (for example, 60 minutes). Thereafter, the resulting biological sample preservative is slowly returned to normal temperature and normal pressure to obtain a freeze-dried biological sample preservative.
- the freeze-drying process or the tableting process after the freeze-drying process can be processed into a desired form through a granulation process.
- the biological sample preservative produced in the first addition step and stirring step of the dehydration step considering the convenience of storing and carrying the biological sample preservative itself, it is further divided into a dry form, a solid form, a powder form, and a powder form. It is also possible to process it into a given solid form such as anhydrous form, granular form and the like.
- a given solid form such as anhydrous form, granular form and the like.
- a necessary amount of container containing the biological sample preservative (solution) produced by the above steps is placed in a vacuum device and left for a predetermined time (for example, 24 hours). After that, the resulting biological sample preservative is slowly returned to normal pressure to obtain a dehydrated biological sample preservative. After the dehydration step, the tableting step can be processed into a desired form through a granulation step.
- a desired biological sample preservative can be produced through the first addition step and stirring step, and optionally the freeze-drying step or dehydration step.
- the biological sample preservative manufactured through the above manufacturing process contains the following components. That is, the biological sample preservative contains 1.0 to 10.0 mol/L, more preferably 1.7 to 5.0 mol/L of "a polyatomic monovalent cation represented by the chemical formula NH4 + " in a predetermined solvent. or a compound composed of said polyatomic monovalent cations.
- the biological sample preservative optionally contains 0.004 to 10.000 mol/L, more preferably 0.010 to 5.000 mol/L "buffer”, 0.004 to 10.000 mol/L , more preferably 0.006-0.500 mol/L of a “chelating agent”, 0.001-1.0% by weight of a “stabilizer”, more preferably 0.01-0.10% by weight, and 0 0.001 to 1.0% by weight, more preferably 0.01 to 0.10% by weight of a "bactericidal/antibacterial agent”.
- the biological sample preservation agent may contain 0.25-30% by weight, more preferably 0.1-10.0% by weight of "excipients".
- the biological sample preservative produced through the above production process has a pH of 4.0 to 10.0, more preferably 6.0 to 8, by adding a pH adjuster or the like. .0. This makes it possible to further improve the storage stability of the biological sample.
- additives such as surfactants, pH adjusters, and colorants may be included as appropriate, although not described in detail.
- ⁇ Method of preserving biological samples using the biological preservatives for example, organs, tissues, cells (including cultured cells), body fluids, nucleic acids, proteins, or combinations thereof may be stored at room temperature.
- the biological sample preservative produced by the first adding step and stirring step is dispensed into a predetermined container (eg, vial bottle, microtube, etc.).
- a biological sample such as an organ, tissue, cell (including cultured cells), body fluid, nucleic acid, protein, or a combination thereof collected from a living body is immersed in the container and placed at room temperature (for example, 5 to 50 ° C.). , more preferably 10 to 40° C.). This makes it possible to store the collected biological sample at room temperature.
- each component is dissolved in a predetermined solvent. It can be used after being dissolved so as to have the concentration of the biological sample preservative in the state (the concentration may be appropriately adjusted according to the amount of the solvent).
- the solvent pure water is typically used, but filtered water treated by filtration, distillation, deionization, or a combination thereof, purified water, distilled water, deionized water, or a combination thereof. Water or water containing these treated water may be used.
- a heat-resistant bottle with a predetermined capacity (2 L glass medium bottle (manufactured by Thermo Fisher Scientific)) is filled with pure water as a solvent, and a stirrer with temperature control (product name: hot stirrer REXIM RSH-4DN (manufactured by AS ONE)) is added. was set to 37° C. and stirred at a rotation speed of 60 rpm. Then, buffers as described in Tables 1-3 below were added and further stirred until the buffers were completely dissolved.
- ammonium sulfate and other components listed in Tables 1 to 3 below are added at concentrations listed in Table 1 below, respectively, and stirred until each component is completely dissolved, and each biological sample preservative (Example 1 to Example 9) were produced.
- Example 1 The biological sample preservative of Example 1 was dispensed from each heat-resistant bottle, and 1 mL each of the undiluted solution, the 1/2 diluted solution, and the 1/4 diluted solution were dispensed into 1.5 mL microtubes. was done. Then, as a biological sample, 1.3 mg of mouse liver was collected, placed in a microtube in which each biological sample preservative was dispensed, and immersed in the biological sample preservative. At this time, as a negative control, 1 mL of phosphate-buffered saline was dispensed into a 1.5-mL microtube, and 1.3 mg of mouse liver was similarly immersed in the phosphate-buffered saline. Then, each biological sample placed in each microtube was stored at 37° C. under normal pressure for 24 hours.
- RNA extraction was performed using a commercially available RNA extraction kit (product name: RNeasy Plus Mini Kit (manufactured by QIAGEN)) according to the method specified by the kit. Then, the storage stability of the biological sample was evaluated by measuring the concentration of RNA obtained from each biological sample in each microtube. The concentration of RNA was measured using an electrophoresis system device (product name: Bioanalyzer 2100 (manufactured by Agilent)) according to the method specified by the device.
- FIG. 1 shows the results of 24 hours at 37° C. of mouse liver in the stock solution, 1/2 dilution, 1/4 dilution, and phosphate-buffered saline prepared as a negative control of the biological sample preservative of Example 1. Images of each microtube after storage are shown.
- Table 4 shows the concentrations of RNA obtained from mouse livers preserved in the stock solution, 1/2 dilution, 1/4 dilution, and phosphate-buffered saline of the biological sample preservative of Example 1. .
- the storage condition of the stored biological sample deteriorates as the concentration of the components contained in each biological sample preservative decreases, such as the undiluted solution, the 1/2 diluted solution, and the 1/4 diluted solution. , it was confirmed that the solution of the biological sample preservative also causes turbidity.
- the solution of the biological sample preservative also causes turbidity.
- turbidity comparable to that of phosphate-buffered saline occurs.
- each concentration of RNA collected from the biological sample after storage also increased according to the concentration of each component of the biological sample preservative.
- concentration of RNA extracted from the biological sample was was equivalent to the concentration of RNA tested.
- concentration of RNA extracted from the biological sample was lower than that of the RNA extracted from the biological sample preserved in phosphate-buffered saline. Compared with the concentration of , it showed a clearly high value.
- the concentration of RNA extracted from the biological sample was compared with the concentration of RNA extracted from the biological sample preserved in phosphate-buffered saline. Then, it showed a very high numerical value (more than twice). That is, from these results, the effect of preserving a biological sample depends on the concentration of the biological sample preservative of Example 1, and from the undiluted solution and the 1/2 diluted solution of the biological sample preservative of Example 1, A very high preservation effect of the sample was confirmed.
- Example 2 1 mL of each of the biological sample preservatives of Examples 1 to 9 was dispensed from each heat-resistant bottle and dispensed into a 1.5 mL microtube. Then, 40 mg of mouse liver was collected as a biological sample, placed in a microtube in which the biological sample preservatives of Examples 1 to 9 had been dispensed, and immersed in the biological sample preservatives. At this time, 1 mL of phosphate-buffered saline was dispensed into a 1.5-mL microtube as a subject, and 40 mg of mouse liver was similarly immersed in the phosphate-buffered saline. Then, each biological sample placed in each microtube was stored at 37° C. under normal pressure for 24 hours.
- RNA extraction was performed in the same manner as in Experiment 1.
- FIG. 2 shows images of microtubes after mouse liver was preserved at 37° C. for 24 hours in each biological sample preservative solution of Examples 1 to 9 and in phosphate-buffered saline prepared as a negative control. indicates
- a positive control 40 mg of mouse liver was collected, frozen at ⁇ 80° C. in a microtube and stored, and the image was also taken in the same manner.
- Table 5 also shows the concentrations of RNA obtained from mouse livers preserved in each of the biological sample preservatives of Examples 1-9 and in phosphate-buffered saline.
- any of the biological samples stored at room temperature in each of the biological sample preservative solutions of Examples 1 to 9 maintained the same condition as the biological sample stored at ⁇ 80° C. prepared as a positive control. Also, turbidity of each biological sample preservative solution was not confirmed.
- the biological sample preserved in phosphate-buffered saline prepared as a negative control clearly produced excessive turbidity compared to the biological samples of Examples 1-9. That is, it was confirmed that all of the biological sample preserving solutions of Examples 1 to 9 had an extremely good biological sample preserving effect even at room temperature.
- each concentration of RNA extracted from biological samples stored at room temperature in each of the biological sample preservative solutions of Examples 1 to 9 was preserved in phosphate-buffered saline prepared as a negative control. All of the measured concentrations were 2.9 times or more higher than the concentration of RNA extracted from the biological sample.
- the concentration of RNA extracted from a biological sample stored at room temperature in the biological sample preservative solution of Example 4 is equivalent to the concentration of RNA extracted from a biological sample frozen at -80°C and prepared as a positive control.
- the concentration of RNA extracted from the biological sample stored at room temperature in the biological sample preservative solution of Example 9 exceeded 1.3 times. That is, from these results, it was confirmed that all of the biological sample preservatives of Examples 1 to 9 exhibited extremely high preserving effects on biological samples.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Dentistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Environmental Sciences (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22928595.2A EP4484546A4 (en) | 2022-02-24 | 2022-02-24 | BIOLOGICAL SAMPLE PRESERVATIVE, BIOLOGICAL SAMPLE PRESERVATIVE PRODUCTION PROCESS, BIOLOGICAL SAMPLE PRESERVATION PROCESS, AND BIOLOGICAL SAMPLE PRESERVATION KIT |
| JP2024502314A JP7893508B2 (ja) | 2022-02-24 | 2022-02-24 | 生体組織または生体組織中のrna保存剤の製造方法 |
| US18/840,234 US20250176532A1 (en) | 2022-02-24 | 2022-02-24 | Biological sample preservative, production method of biological sample preservative, preservation method of biological sample, and kit for preserving biological sample |
| PCT/JP2022/007491 WO2023162065A1 (ja) | 2022-02-24 | 2022-02-24 | 生体試料保存剤、生体試料保存剤の製造方法、生体試料保存方法及び生体試料保存のためのキット |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/JP2022/007491 WO2023162065A1 (ja) | 2022-02-24 | 2022-02-24 | 生体試料保存剤、生体試料保存剤の製造方法、生体試料保存方法及び生体試料保存のためのキット |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2023162065A1 true WO2023162065A1 (ja) | 2023-08-31 |
Family
ID=87764987
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2022/007491 Ceased WO2023162065A1 (ja) | 2022-02-24 | 2022-02-24 | 生体試料保存剤、生体試料保存剤の製造方法、生体試料保存方法及び生体試料保存のためのキット |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20250176532A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4484546A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7893508B2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023162065A1 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025167593A1 (zh) * | 2024-02-06 | 2025-08-14 | 上海细胞治疗集团股份有限公司 | 生物样本的存储保护剂、采集卡、存储和检测方法 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000006780A1 (en) * | 1998-07-31 | 2000-02-10 | Ambion, Inc. | Methods and reagents for preserving rna in cell and tissue samples |
| WO2013115322A1 (ja) * | 2012-02-02 | 2013-08-08 | タカラバイオ株式会社 | 細胞の保存方法 |
| WO2016201126A1 (en) * | 2015-06-09 | 2016-12-15 | President And Fellows Of Harvard College | Compositions and methods for tissue preservation at ambient or subnormothermic temperatures |
| JP2020039261A (ja) | 2018-09-07 | 2020-03-19 | 三菱製紙株式会社 | 凍結保存液 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57130995A (en) * | 1981-02-04 | 1982-08-13 | Ajinomoto Co Inc | Freeze drying method |
| JPH08126685A (ja) * | 1994-01-26 | 1996-05-21 | Shionogi & Co Ltd | デキストラン類の凍結乾燥方法 |
| WO2011069528A1 (en) * | 2009-12-09 | 2011-06-16 | Curevac Gmbh | Lyophilization of nucleic acids in lactate-containing solutions |
| CN112961779A (zh) * | 2021-03-08 | 2021-06-15 | 海南微氪生物科技股份有限公司 | 一种大肠杆菌冷冻干燥的质控小球的制备方法 |
-
2022
- 2022-02-24 EP EP22928595.2A patent/EP4484546A4/en active Pending
- 2022-02-24 WO PCT/JP2022/007491 patent/WO2023162065A1/ja not_active Ceased
- 2022-02-24 JP JP2024502314A patent/JP7893508B2/ja active Active
- 2022-02-24 US US18/840,234 patent/US20250176532A1/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000006780A1 (en) * | 1998-07-31 | 2000-02-10 | Ambion, Inc. | Methods and reagents for preserving rna in cell and tissue samples |
| WO2013115322A1 (ja) * | 2012-02-02 | 2013-08-08 | タカラバイオ株式会社 | 細胞の保存方法 |
| WO2016201126A1 (en) * | 2015-06-09 | 2016-12-15 | President And Fellows Of Harvard College | Compositions and methods for tissue preservation at ambient or subnormothermic temperatures |
| JP2020039261A (ja) | 2018-09-07 | 2020-03-19 | 三菱製紙株式会社 | 凍結保存液 |
Non-Patent Citations (1)
| Title |
|---|
| See also references of EP4484546A4 |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025167593A1 (zh) * | 2024-02-06 | 2025-08-14 | 上海细胞治疗集团股份有限公司 | 生物样本的存储保护剂、采集卡、存储和检测方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4484546A1 (en) | 2025-01-01 |
| US20250176532A1 (en) | 2025-06-05 |
| JP7893508B2 (ja) | 2026-07-22 |
| EP4484546A4 (en) | 2025-11-12 |
| JPWO2023162065A1 (cg-RX-API-DMAC7.html) | 2023-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100771388B1 (ko) | 생물학적 물질용 보존 및 저장 배지 | |
| US6060233A (en) | Methods for the lyophilization of platelets, platelet membranes or erythrocytes | |
| Conrad et al. | Stabilization and preservation of Lactobacillus acidophilus in saccharide matrices | |
| EP1231837B1 (en) | Preservation of sensitive biological material | |
| JP2004505024A5 (cg-RX-API-DMAC7.html) | ||
| US5736313A (en) | Method of lyophilizing platelets by incubation with high carbohydrate concentrations and supercooling prior to freezing | |
| JP2008530066A (ja) | 乾燥製品 | |
| CN115024310A (zh) | 一种细胞冻干保存剂及其制备方法 | |
| CN111979299A (zh) | 一种核酸提取样本保存液及其制备方法 | |
| JP4947948B2 (ja) | 細胞保存液 | |
| US20250176532A1 (en) | Biological sample preservative, production method of biological sample preservative, preservation method of biological sample, and kit for preserving biological sample | |
| US10611996B2 (en) | Preservation and storage of biological specimens | |
| WO2004084629A1 (fr) | Procede de lyophilisation et de cryoconservation de cals et cryoprotecteur utilise | |
| FR2510355A1 (fr) | Milieu concu pour recevoir de la semence de dindon afin de la diluer et d'augmenter sa duree de vie, et procede de conservation de semence de dindon a l'aide de ce milieu | |
| EP2639298B1 (en) | The method for preparing human semen for in vitro fertilization or for artificial insemination | |
| EP3178927B1 (en) | Protein-stabilizing agent and protein-stabilizing method | |
| CN118547050A (zh) | 一种血液检测保存试剂、制备方法和检测试剂盒 | |
| US6040132A (en) | Methods for the lyophilization of living biological materials | |
| CA2257497A1 (en) | Compositions and methods for the preservation of living tissues | |
| JP3937019B2 (ja) | 微生物保存用分散媒及び微生物保存用容器 | |
| RU2109290C1 (ru) | Стабилизирующий состав для получения лиофилизированных препаратов на основе конъюгата антииммуноглобулина g и пероксидазы хрена | |
| JPH08325101A (ja) | 動物組織保存方法 | |
| JP7755927B2 (ja) | 血小板の活性化剤 | |
| JP7716851B2 (ja) | 凍結保存液 | |
| SU1246967A1 (ru) | Состав дл криоконсервации миелокариоцитов |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22928595 Country of ref document: EP Kind code of ref document: A1 |
|
| ENP | Entry into the national phase |
Ref document number: 2024502314 Country of ref document: JP Kind code of ref document: A |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 18840234 Country of ref document: US |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 202417070298 Country of ref document: IN |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2022928595 Country of ref document: EP |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| ENP | Entry into the national phase |
Ref document number: 2022928595 Country of ref document: EP Effective date: 20240924 |
|
| WWP | Wipo information: published in national office |
Ref document number: 18840234 Country of ref document: US |